Novel engineered recombinant ACE2 reduces SARS-CoV-2-induced COVID-19 without cardiotoxic side effects
Molecular Therapy · 2024
DOI: 10.1016/j.ymthe.2024.01.003 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Therapy, 2024. Verfasst von Federico Ávila-Moreno. Beteiligte Einrichtung: Lung Diseases and Functional Epigenomics Laboratory (LUDIFE), Biomedicine Research Unit (UBIMED), Facultad de Estudios Superiores-Iztacala (FES-Iztac…. Hauptthemen laut MEDLINE: COVID-19. Die Arbeit nennt 12 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
In a recent issue of Molecular Therapy, 1 Feng H. Yang L. Yang H. Cheng D. Li M. Song E. Xu T. A cardiotoxicity-eliminated ACE2 variant as a pan-inhibitor against coronavirus cell invasion. Mol. Ther. 2024; 32: 218-226 Abstract Full Text Full Text PDF PubMed Scopus (1) Google Scholar Song et al. describe an engineered human angiotensin-converting enzyme 2 (ACE2), the entry receptor for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). 2 Li W. Moore M.J. Vasilieva N. Sui J. Wong S.K. Berne M.A. Somasundaran M. Sullivan J.L. Luzuriaga K. Greenough T.C. et al. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature. 2003; 426: 450-454 Crossref PubMed Scopus (4498) Google Scholar ACE2’s strong expression in type II alveolar, arterial, venous endothelial, and smooth muscle cells allows SARS-CoV-2 to infect and invade lung and heart tissues through interaction with viral spike proteins (SPs). 3 Zhou P. Yang X.-L. Wang X.-G. Hu B. Zhang L. Zhang W. Si H.-R. Zhu Y. Li B. Huang C.-L. et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020; 579: 270-273 Crossref PubMed Scopus (14260) Google Scholar Song and colleagues modified human ACE2 by introducing 4 genetic mutations in key sites (H345/H374/H378/H505L) of the structural core of ACE2’s enzymatic activity, referred to as human recombinant ACE2-4mu (hrACE2-4mu) protein. The hrACE2-4mu protein showed high binding affinity to viral SPs, including those derived from multiple SARS-CoV-2 variants (e.g., Beta, Delta, and Omicron). Moreover, unlike wild-type hrACE2, hrACE2-4mu did not induce cardiac fibrosis in two in vivo models (Syrian golden hamsters and guinea pigs), making it a potentially safe pan-therapy for coronavirus disease 2019 (COVID-19). This potential therapeutic agent is the result of decades of research into the biological function of ACE2, which I will briefly cover in this editorial.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Lung Diseases and Functional Epigenomics Laboratory (LUDIFE), Biomedicine Research Unit (UBIMED), Facultad de Estudios Superiores-Iztacala (FES-Iztacala), Universidad Nacional Autónoma de México, (UNAM), México State 54…
Zitieren
APA
Ávila-Moreno, F. (2024). Novel engineered recombinant ACE2 reduces SARS-CoV-2-induced COVID-19 without cardiotoxic side effects. Molecular Therapy. https://doi.org/10.1016/j.ymthe.2024.01.003
Vancouver
Ávila-Moreno F. Novel engineered recombinant ACE2 reduces SARS-CoV-2-induced COVID-19 without cardiotoxic side effects. Molecular Therapy. 2024. doi:10.1016/j.ymthe.2024.01.003
BibTeX
@article{vilaMoreno2024,
author = {Ávila-Moreno, Federico},
title = {Novel engineered recombinant ACE2 reduces SARS-CoV-2-induced COVID-19 without cardiotoxic side effects},
journal = {Molecular Therapy},
year = {2024},
doi = {10.1016/j.ymthe.2024.01.003}
}
EUVIMED